Problem

Ruma Care addresses the administrative and financial risk that biologic infusion clinics face when obtaining reimbursement for expensive specialty medications. Biologics can cost $80,000–$150,000 or more per patient annually, while clinics often buy and hold inventory before reimbursement. Insurers deny these medications at a reported 37% annual rate, and each payer applies different, frequently changing requirements. When an authorization fails—or a patient is infused before paperwork is cleared—the clinic can be left covering the drug’s cost. The core use case is helping a high-volume infusion clinic prevent denied buy-and-bill claims while reducing the staff time spent on forms, faxes, portals, appeals, and phone calls.

Product / Service

Ruma Care is an AI-enabled operations and prior-authorization platform built specifically for biologic infusion clinics. It pulls patient, diagnosis, medication, insurance, and site-of-care data from the clinic’s EHR; identifies the payer’s requirements; selects and completes the appropriate forms; flags missing documentation; and supports insurer follow-up through approval. It also enrolls patients in copay-assistance programs, bringing a process that can span more than 70 portals, paper forms, and manual calls into one workflow. The intended benefit is faster patient access to treatment, fewer denials and reimbursement losses, and less repetitive administrative work for care teams.

Market

Ruma Care competes in B2B healthcare IT, particularly specialty-medication access, electronic prior-authorization automation, and infusion-clinic revenue-cycle operations. Its competitors include general ePA platforms such as CoverMyMeds, Surescripts, and Availity, as well as EHR-native prior-authorization tools. Ruma’s differentiation is its narrow focus on biologic and buy-and-bill infusion workflows, combining prior authorization, copay enrollment, denial learning, and reimbursement support rather than treating authorization as a standalone pharmacy workflow.

The company is an active Y Combinator Winter 2026 startup and reports that its product is live across clinics in California and Nevada. Its public materials cite a 50% reduction in denial rates and a 20-fold reduction in staff time per prior authorization, alongside testimonials from rheumatology, arthritis, and headache-care practices. These are company-reported traction metrics; the available evidence establishes live deployments but does not disclose revenue or a customer count, so Ruma Care should be characterized as an early commercial-stage company rather than definitively pre-revenue.